DWA
NVCT icon

Dorsey Wright & Associates’s Nuvectis Pharma NVCT Stock Holding History

Dorsey Wright & Associates’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,396
Closed -$18K – 239
2023
Q3 		$18K Sell
1,396
-48
-3% -$695 0.01% 269
2023
Q2 		$23.1K Buy
+1,444
New +$23K 0.01% 233

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Dorsey Wright & Associates's NVCT Position: Q4 2023 in Review

Dorsey Wright & Associates sold out of Nuvectis Pharma (NVCT) in Q4 2023, closing a stake of 1,396 shares — an estimated $18K sold.

Dorsey Wright & Associates first reported a position in NVCT in Q2 2023 and held it in 2 quarters. The position peaked at $23.1K in Q2 2023. 36 funds tracked by Wall St. Rank hold NVCT as of Q4 2023.

  • Dorsey Wright & Associates reported no remaining Nuvectis Pharma position as of Q4 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 1,396 Nuvectis Pharma shares in Q4 2023, an estimated $18K.
  • Dorsey Wright & Associates first reported a position in Nuvectis Pharma in Q2 2023 and held it in 2 quarters.
  • Dorsey Wright & Associates's Nuvectis Pharma position peaked at $23.1K in Q2 2023.
  • 36 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q4 2023.

Based on Dorsey Wright & Associates's 13F filing for Q4 2023, filed 13 Feb 2024.